# CapsoVision, Inc: overview CV · Nasdaq · CIK 1378325 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cv.md) · [Financials](/companies/cv/financials.md) · [Filings](/companies/cv/filings.md) · [Insiders](/companies/cv/insiders.md) Latest reported revenue: [$3.6m](/filings/0001378325-26-000036.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001378325-26-000036). ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [2,966](/filings/0001378325-25-000040.md) | [3,452 d](/filings/0001378325-26-000010.md) | [2,783](/filings/0001378325-26-000021.md) | [3,315](/filings/0001378325-26-000036.md) | [3,538](/filings/0001378325-25-000040.md) | [3,918 d](/filings/0001378325-26-000010.md) | [2,792](/filings/0001378325-26-000021.md) | [3,643](/filings/0001378325-26-000036.md) | | Gross margin | % | [55.9%](/filings/0001378325-25-000040.md) | [50.2% d](/filings/0001378325-26-000010.md) | [53.7%](/filings/0001378325-26-000021.md) | [54.6%](/filings/0001378325-26-000036.md) | [54.1%](/filings/0001378325-25-000040.md) | [49.9% d](/filings/0001378325-26-000010.md) | [47.6%](/filings/0001378325-26-000021.md) | [51.4%](/filings/0001378325-26-000036.md) | | Operating margin | % | [(195.7%)](/filings/0001378325-25-000040.md) | [(134.2%) d](/filings/0001378325-26-000010.md) | [(193.4%)](/filings/0001378325-26-000021.md) | [(140.3%)](/filings/0001378325-26-000036.md) | [(226.7%)](/filings/0001378325-25-000040.md) | [(190.5%) d](/filings/0001378325-26-000010.md) | [(254.0%)](/filings/0001378325-26-000021.md) | [(208.1%)](/filings/0001378325-26-000036.md) | | Net margin | % | [(195.3%)](/filings/0001378325-25-000040.md) | [(134.4%) d](/filings/0001378325-26-000010.md) | [(193.1%)](/filings/0001378325-26-000036.md) | [(139.5%)](/filings/0001378325-26-000036.md) | [(223.9%)](/filings/0001378325-25-000040.md) | [(188.7%) d](/filings/0001378325-26-000010.md) | [(251.9%)](/filings/0001378325-26-000036.md) | [(205.4%)](/filings/0001378325-26-000036.md) | | Diluted EPS | $ per share | [(2.79)](/filings/0001378325-25-000040.md) | not reported | [(2.49)](/filings/0001378325-26-000021.md) | [(2.02)](/filings/0001378325-26-000036.md) | [(0.17)](/filings/0001378325-25-000040.md) | not reported | [(0.15)](/filings/0001378325-26-000021.md) | [(0.15)](/filings/0001378325-26-000036.md) | | Free cash flow | $k | [(7,060) d](/filings/0001378325-25-000040.md) | [(5,399) d](/filings/0001378325-26-000010.md) | [(5,026)](/filings/0001378325-26-000021.md) | [(4,556) d](/filings/0001378325-26-000036.md) | [(5,678) d](/filings/0001378325-25-000040.md) | [(7,694) d](/filings/0001378325-26-000010.md) | [(6,114)](/filings/0001378325-26-000021.md) | [(8,403) d](/filings/0001378325-26-000036.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | | Revenue | $m | [11.8](/filings/0001378325-26-000010.md) | [13.6](/filings/0001378325-26-000010.md) | | Gross margin | % | [54.2%](/filings/0001378325-26-000010.md) | [52.9%](/filings/0001378325-26-000010.md) | | Operating margin | % | [(169.4%)](/filings/0001378325-26-000010.md) | [(188.3%)](/filings/0001378325-26-000010.md) | | Net margin | % | [(169.3%)](/filings/0001378325-26-000010.md) | [(186.8%)](/filings/0001378325-26-000010.md) | | Diluted EPS | $ per share | [(9.85)](/filings/0001378325-26-000010.md) | [(1.03)](/filings/0001378325-26-000010.md) | | Free cash flow | $m | [(20.2)](/filings/0001378325-26-000010.md) | [(23.0)](/filings/0001378325-26-000010.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cv/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $14.4m | 1,896,088 | | Added +591,667 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.0m | 1,058,468 | | Added +32,199 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.4m | 578,482 | | Added +143,328 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $3.1m | 410,241 | | Added +154,200 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.8m | 240,425 | | Added +76,039 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $1.7m | 220,095 | | Added +67,761 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $785.5k | 103,630 | | Added +14,998 | | [CHARLES SCHWAB INVESTMENT MANAGEMENT INC](/funds/884546.md) | 2026-06-30 | $601.5k | 79,360 | | Added +17,983 | | [Bank of New York Mellon Corp](/funds/1390777.md) | 2026-06-30 | $568.7k | 75,021 | | Added +25,727 | | [Nuveen, LLC](/funds/1871926.md) | 2026-06-30 | $348.8k | 46,011 | | Added +12,913 | ## Recent filings [All 139 filings](/companies/cv/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-28 | 11:03 ET | [8-K](/filings/0001378325-26-000045.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001378325-26-000045 | | 2026-09-18 | 16:08 ET | [8-K](/filings/0001378325-26-000043.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001378325-26-000043 | | 2026-08-18 | 17:50 ET | [8-K](/filings/0001378325-26-000039.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001378325-26-000039 | | 2026-08-13 | 16:35 ET | [10-Q](/filings/0001378325-26-000036.md) | Quarterly report, period 2026-06-30 | 0001378325-26-000036 | | 2026-08-13 | 16:07 ET | [8-K](/filings/0001378325-26-000035.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001378325-26-000035 | | 2026-07-02 | 16:10 ET | [8-K](/filings/0001378325-26-000026.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure | 0001378325-26-000026 | | 2026-06-12 | 14:14 ET | [8-K](/filings/0001378325-26-000023.md) | 5.07 Shareholder vote results | 0001378325-26-000023 | | 2026-05-14 | 16:35 ET | [10-Q](/filings/0001378325-26-000021.md) | Quarterly report, period 2026-03-31 | 0001378325-26-000021 | | 2026-05-14 | 16:08 ET | [8-K](/filings/0001378325-26-000019.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001378325-26-000019 | | 2026-04-28 | 12:39 ET | [DEF 14A](/filings/0001378325-26-000013.md) | Proxy statement, period 2025-12-31 | 0001378325-26-000013 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001378325-26-000010.md), filed Mar 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ae3e52bf-3d5f-4a89-95dc-9a93918ac280) ## About the filer - CIK: 1378325 - Tickers: CV - Exchange: Nasdaq - SIC code: 3845 Electromedical & Electrotherapeutic Apparatus - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.